Cel-Sci Corporation Common Stock (CVM)
Stock · AMEX · Health Care
$1.56as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$1.46
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fundamentals
- Market cap
- $21.85M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
Cel-Sci Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- CVMCel-Sci Corporation Common Stock$1.56▼ 2.50%Market cap $21.85MP/E —
- JSPRJasper Therapeutics Inc. Common Stock$0.6782▼ 2.98%Market cap $16.98MP/E —$0.3151$2.96
- ALGSAligos Therapeutics Inc. Common Stock$6.93▼ 1.98%Market cap $28.47MP/E —$3.98$13.69
- PASGPassage Bio Inc. Common Stock$4.52▲ 4.39%Market cap $14.40MP/E —$3.29$20
- ESLAEstrella Immunopharma Inc. Common Stock$0.705▼ 2.10%Market cap $30.12MP/E —$0.6781$3.15
- SNTISenti Biosciences Holdings Inc. Common Stock$0.377▼ 0.26%Market cap $11.53MP/E —$0.3305$2.88
- INTSIntensity Therapeutics Inc. Common stock$4.25▲ 0.95%Market cap $11.51MP/E —$3.51$43.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CVM Cel-Sci Corporation Common Stock | $21.85M | — | $1.56 | ▼ 2.50% | |
| JSPR Jasper Therapeutics Inc. Common Stock | $16.98M | — | $0.6782 | ▼ 2.98% | $0.3151$2.96 |
| ALGS Aligos Therapeutics Inc. Common Stock | $28.47M | — | $6.93 | ▼ 1.98% | $3.98$13.69 |
| PASG Passage Bio Inc. Common Stock | $14.40M | — | $4.52 | ▲ 4.39% | $3.29$20 |
| ESLA Estrella Immunopharma Inc. Common Stock | $30.12M | — | $0.705 | ▼ 2.10% | $0.6781$3.15 |
| SNTI Senti Biosciences Holdings Inc. Common Stock | $11.53M | — | $0.377 | ▼ 0.26% | $0.3305$2.88 |
| INTS Intensity Therapeutics Inc. Common stock | $11.51M | — | $4.25 | ▲ 0.95% | $3.51$43.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoYBenzinga · 8/17/2026
- CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral OncologyBenzinga · 8/4/2026
Insider Activity
Insider Actions →Acquired
415.4K
Disposed
0
- TALOR EYAL · June 30, 2026 · Grant2.3K @ $1.04
- PRICHEP PATRICIA B · June 30, 2026 · Grant4.1K @ $1.04
- KERSTEN GEERT R · June 30, 2026 · Grant5.2K @ $1.04
- KERSTEN GEERT R · May 14, 2026 · Buy300.0K @ $1.2
- KERSTEN GEERT R · May 13, 2026 · Buy100.0K @ $1.19
- TALOR EYAL · March 31, 2026 · Grant747 @ $3.21
- PRICHEP PATRICIA B · March 31, 2026 · Grant1.3K @ $3.21
- KERSTEN GEERT R · March 31, 2026 · Grant1.7K @ $3.21
Institutional Ownership
March 31, 2026
- Total shares held
- 696.6K
- Total value held
- $2.24M
- Institutional holders
- 35
Top holders this quarter
- Unknown243.6K
- Unknown91.3K
- Unknown85.3K
- Unknown43.3K
- Unknown41.0K
- Unknown35.9K
- Unknown29.9K
- Unknown27.3K
- Unknown22.6K
- Unknown18.9K
See the full, filterable feed with live charts on the MarketWall dashboard.